MedTrace Logo

Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process

NCT06232421 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2025-07-25

No results posted yet for this study

Summary

The purpose of this study is to estimate efficiency, tolerance, safety of "Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.

Conditions

  • Diabetic Foot Infections
  • Chronic Venous Insufficiency

Interventions

DRUG

Foscelantan

"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1" produced by UNITEHPROM BSU, Republic of Belarus

DRUG

Povidon-iodine

Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus

Sponsors & Collaborators

  • Vitebsk Regional Clinical Hospital

    collaborator OTHER_GOV

  • Unitary Enterprise UNITEHPROM BSU

    collaborator UNKNOWN

  • The 10th Minsk City Clinical Hospital

    collaborator UNKNOWN

  • Research Institute for Physical Chemical Problems of the Belarusian State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2026-04-30
Completion
2026-05-31

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232421 on ClinicalTrials.gov